GlassScriptPhysician profile
Mohamad A Cherry
NPI 1386690840
$239,629.23
in general payments reported to CMS, 2019-2025
80 companies · $35K in 2025
The $35K reported for 2025 was more than what 95% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $22K · 2021: $18K · 2022: $57K · 2023: $40K · 2024: $43K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $61K · Consulting Fee: $32K · Food and Beverage: $12K · Honoraria: $6,580 · Travel and Lodging: $6,562 · Education: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $61,244.00 |
| Consulting Fee | $32,207.25 |
| Food and Beverage | $11,781.99 |
| Honoraria | $6,580.00 |
| Travel and Lodging | $6,561.68 |
| Education | $127.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $59,466.46 | 2019-2025 | Reblozyl, Opdivo, Eliquis |
| Genzyme Corporation | $49,048.12 | 2019-2025 | |
| Secura Bio, INC. | $15,694.26 | 2022-2023 | Copiktra |
| Celgene Corporation | $14,473.92 | 2019-2025 | Reblozyl, Pomalyst, Breyanzi |
| Kite Pharma, INC. | $12,451.15 | 2019-2025 | Yescarta |
| Genentech, INC. | $10,862.50 | 2020-2022 | |
| Pfizer INC. | $10,031.34 | 2019-2025 | |
| Incyte Corporation | $8,404.92 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Gilead Sciences, INC. | $6,780.58 | 2019-2025 | Trodelvy |
| Abbvie INC. | $6,484.71 | 2019-2023 | Epkinly |
| Pharmacosmos Therapeutics INC. | $5,344.92 | 2022-2024 | Monoferric |
| Ipsen Biopharmaceuticals, INC | $5,317.34 | 2019-2025 | Onivyde |
| Janssen Biotech, INC. | $4,935.31 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Novartis Pharmaceuticals Corporation | $4,448.34 | 2019-2025 | |
| Syndax Pharmaceuticals, INC. | $3,720.11 | 2025 | Revuforj |
Show all 77 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $3,681.53 | 2021-2024 | |
| Pharmaessentia USA Corporation | $3,307.37 | 2022-2025 | Besremi |
| Agios Pharmaceuticals, INC. | $2,908.88 | 2020-2025 | Pyrukynd |
| Jazz Pharmaceuticals INC. | $2,146.16 | 2019-2023 | |
| Daiichi Sankyo INC. | $1,385.73 | 2019-2025 | Enhertu, Vanflyta, Injectafer |
| Merck Sharp & Dohme LLC | $913.54 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $883.33 | 2019-2025 | Calquence, Lynparza, Tagrisso |
| Amgen INC. | $721.41 | 2019-2023 | Kyprolis, Nplate, Vectibix |
| Seagen INC. | $715.15 | 2019-2023 | Tukysa, Padcev |
| Eisai INC. | $641.36 | 2019-2025 | |
| Glaxosmithkline, LLC. | $540.40 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Boehringer Ingelheim Pharma Gmbh & Co.Kg | $511.28 | 2020 | |
| Alexion Pharmaceuticals, INC. | $312.86 | 2019-2024 | Ultomiris |
| Genentech USA, INC. | $257.20 | 2019-2024 | Venclexta, Lunsumio, Rozlytrek |
| Regeneron Healthcare Solutions, INC. | $232.04 | 2019-2025 | Libtayo |
| Lilly USA, LLC | $227.84 | 2020-2024 | Verzenio, Jaypirca, Retevmo |
| Astellas Pharma US INC | $211.25 | 2019-2025 | Xospata, Padcev, Vyloy |
| Karyopharm Therapeutics INC. | $209.31 | 2020-2023 | Xpovio |
| Bayer Healthcare Pharmaceuticals INC. | $209.05 | 2019-2025 | |
| Array Biopharma INC | $179.45 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Takeda Pharmaceuticals U.S.A., INC. | $151.53 | 2019-2024 | Vpriv, Fruzaqla |
| Sun Pharmaceutical Industries INC. | $150.55 | 2023-2025 | Yonsa, Odomzo |
| Adaptive Biotechnologies Corporation | $128.83 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $119.62 | 2019-2023 | Rezlidhia, Tavalisse |
| Kerecis Limited | $110.46 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Exelixis INC. | $86.12 | 2021-2025 | Cabometyx |
| Foundation Medicine, INC. | $81.90 | 2021-2023 | |
| Genmab U.S., INC. | $81.74 | 2022-2024 | Epkinly |
| Taiho Oncology, INC. | $79.67 | 2019-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $78.70 | 2019-2022 | |
| Emd Serono, INC. | $66.83 | 2023-2025 | Bavencio |
| Morphosys, US INC. | $60.97 | 2022-2023 | Monjuvi |
| Eusa Pharma (US) LLC | $58.10 | 2019 | |
| Epizyme, INC. | $57.67 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $57.31 | 2020-2021 | |
| Puma Biotechnology, INC. | $52.55 | 2019-2022 | |
| Tersera Therapeutics LLC | $43.28 | 2022-2024 | Zoladex |
| Janssen Pharmaceuticals, INC | $42.22 | 2022 | |
| Mirati Therapeutics, INC. | $38.00 | 2024 | Krazati |
| Blueprint Medicines Corporation | $33.12 | 2023-2024 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.87 | 2019-2021 | |
| Caris Mpi, INC. | $26.19 | 2025 | Mi Cancer Seek |
| Acrotech Biopharma INC. | $24.92 | 2021 | |
| Sirtex Medical INC | $23.73 | 2019 | |
| Emmaus Medical, INC. | $21.33 | 2023 | Endari |
| Immunogen, INC. | $21.13 | 2024 | Elahere |
| Cumberland Pharmaceuticals, INC. | $19.00 | 2025 | Sancuso |
| Macrogenics, INC. | $18.13 | 2022 | |
| Stemline Therapeutics INC. | $18.12 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $17.06 | 2025 | Akynzeo |
| Galvanize Therapeutics, INC | $15.76 | 2024 | Aliya System |
| Deciphera Pharmaceuticals INC. | $14.89 | 2025 | Qinlock, Romvimza |
| Acceleron Pharma, INC. | $14.76 | 2021 | |
| Kyowa Kirin, INC. | $14.59 | 2020 | |
| Tesaro, INC. | $14.51 | 2019 | |
| Advanced Accelerator Applications | $14.47 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $14.46 | 2020 | |
| Dova Pharmaceuticals | $14.14 | 2019 | |
| Duchesnay USA Incorporated | $14.04 | 2022 | |
| Azurity Pharmaceuticals, INC. | $13.98 | 2024 | Vivimusta |
| Cti Biopharma Corp. | $13.18 | 2022 | |
| Adc Therapeutics America, INC. | $12.68 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3,737.97 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamad Cherry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.